J.-M. Bréchot - Concepedia

Author

J.-M. Bréchot

Also Known As

J M Bréchot, J. Brechot, J. M. Bréchot, J.-M. Brechot, J.-M. Bréchot, J.M Bréchot, J.M. Brechot, J.M. Bréchot, J.‐F. Bréchot, Jeanne-Marie Brechot

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

Hôtel-Dieu de Paris Sorbonne Université Centre Hospitalier Universitaire de Tours Hôpital Tenon Hôpital Saint-Louis

About

J.-M. Bréchot is an author at Hôtel-Dieu de Paris specializing in lung cancer, medicine, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	550
2	Health Sciences	3	3	368
3	Cell Biology	1	1	74
4	Cellular Physiology	1	1	74
5	Immunology	1	1	74

J.-M. Bréchot

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Preoperative Chemotherapy Followed by Surgery Compared With Primary Surgery in Resectable Stage I (Except T1N0), II, and IIIa Non–Small-Cell Lung Cancer A Depierre, B. Milleron, Denis Moro‐Sibilot, Journal of Clinical Oncology	2002	569
Subcutaneous heparin treatment increases survival in small cell lung cancer B Lebeau, Claude Chastang, J.-M. Bréchot, Cancer	1994	277
Baseline results of the Depiscan study: A French randomized pilot trial of lung cancer screening comparing low dose CT scan (LDCT) and chest X-ray (CXR) Thierry Blanchon, J.-M. Bréchot, Philippe Greniér, Lung Cancer Medical ImagingCancer DetectionMedicineCancer ScreeningDepiscan Study	2007	271
Protein‐Energy Malnutrition in Elderly Medical Patients Thierry Constans, Yannick Bacq, J.-M. Bréchot, Journal of the American Geriatrics Society	1992	211
Blood vessel and lymphatic vessel invasion in resected nonsmall cell lung carcinoma: Correlation with TNM stage and disease free and overall survival J.-M. Bréchot, Sylvie Chevret, Marie-Christine Charpentier, Cancer	1996	103
Different Pattern of MRP Localization in Ciliated and Basal Cells from Human Bronchial Epithelium J.-M. Bréchot, Ilse Hurbain, Anne Fajac, Journal of Histochemistry & Cytochemistry Basal CellsInflammatory Lung DiseaseTumor MicroenvironmentEpendymaHuman Bronchial Epithelium	1998	74
Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients J.-M. Bréchot, Sylvie Chevret, J Nataf, European Journal of Cancer Prognostic BiomarkersAdvanced Lung DiseaseOther Tumour MarkersMedicinePrognostic Value	1997	65
Failure of the perioperative PCV neoadjuvant polychemotherapy in resectable bronchogenic non-small cell carcinoma results from a randomized phase II trial Bertrand Dautzenberg, Jacques Bénichou, P Allard, Cancer Surgical OncologyImmediate SurgeryMedicineClinical TrialsOutcomes Research	1990	55
Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy fornon-small-cell lung cancer Élisabeth Quoix, B Lebeau, A Depierre, Annals of Oncology OncologyMedicineMetronomic TherapyPhase Ii StudyBronchial Neoplasm	2003	43
Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study) Jean‐François Morère, J.-M. Bréchot, Virginie Westeel, Lung Cancer Docetaxel ChemotherapyIfct-0301 StudyMedicineMetronomic TherapyClinical Trials	2010	42

Page 1